Immunic’s lead oral small molecule has failed to hit the primary endpoint of a phase 2 trial in patients with progressive ...

Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three ...

Sanofi has bolstered the case for its oral BTK inhibitor tolebrutinib as a treatment for multiple sclerosis (MS), due to be filed for approval in the latter half of this year, with new data in a ...

More data are needed on its efficacy and safety in treating relapsing multiple sclerosis. In two phase ... Supported by Sanofi. Disclosure forms provided by the authors are available with the ...

Discover why BTK inhibitors have attracted interest for treating multiple sclerosis, as a few late-stage candidates close in ...

Tolebrutinib was found to delay disability progression in people with nonrelapsing secondary progressive MS in a Phase 3 ...

Additionally, results from the GEMINI 1 and 2 phase 3 studies, evaluating tolebrutinib in people with relapsing multiple sclerosis were ... Report an Issue Sanofi NewsMORE Related Stocks Indices ...

Throughout the course of multiple sclerosis, gradually progressive neurologic ... full text of this article at NEJM.org. Supported by Sanofi. Disclosure forms provided by the authors are available ...

Hoffman-LaRoche, Novartis, and Sanofi. Source Reference: Oh J, et al "Tolebrutinib versus teriflunomide in relapsing multiple sclerosis" N Engl J Med 2025; DOI: 10.1056/NEJMoa2415985.

--U.S. FDA Delays: Sanofi is potentially exposed to any delays in reviews due to recently announced staff firings at the U.S. Food and Drug Administration. Its anti-inflammatory drug Dupixent was ...

About multiple sclerosis Multiple sclerosis is a chronic ... Tolebrutinib represents Sanofi's commitment to developing innovative treatments that address the underlying causes of neurological ...

Data from an open-label extension of VISIONARY-MS support an association between gold nanocrystals and neuronal repair and remyelination in patients with stable multiple sclerosis and visual deficits, ...